摘要
目的:探讨普罗布考对不稳定型心绞痛(UAP)患者血清明胶酶的影响。方法:连续入选UAP患者80例,随机分为普罗布考治疗组(40例)和常规治疗组(40例)。常规治疗组采用硝酸酯类、阿司匹林、β受体阻滞剂等常规药物治疗;普罗布考组在常规治疗基础上加用普罗布考口服,观察治疗前及治疗一个月后血清明胶酶水平。结果:与治疗前比较,普罗布考治疗组治疗后基质金属蛋白酶(MMP)-2[(54.04±6.54)ng/ml比(32.43±1.81)ng/ml]、MMP-9[(56.33±7.25)ng/ml比(34±1.45)ng/ml]水平均明显下降(P均<0.01),且明显低于常规治疗组治疗后[MMP-2:(37.21±2.86)ng/ml、MMP-9:(39.96±1.75)ng/ml],P<0.05。结论:普罗布考能促进不稳定型心绞痛患者血清明胶酶水平的下降,起到稳定粥样斑块的作用。
Objective： To investigate effects of probucol on serum levels of gelatinases in patients with unstable angina pectoris （UAP）. Methods： A total of 80 UAP patients were continuously enrolled and randomly divided into probu- col treatment group （n= 40） and routine treatment group （n= 40）. Routine treatment group was given routine medi- cal treatment with nitrates, aspirin and ^-receptor blocker etc; probucol group was given probucol oral additionally based on routine treatment. Serum levels of gelatinases were examined before and one month after treatment. Results： Compared with before treatment, levels of matrix metalloproteinase （MMP） --2 [ （54.04±6.54） ng/ml vs. （32.43±1.81） ng/ml] and MMP--9 [- （56.33±7.25） ng/ml vs. （34±1.45） ng/ml] significantly decreased in pro- bucol treatment group after treatment （P〈0.01 both）, and significantly lower than those of routine treatment group EMMP-2： （37.21±2.86） ng/ml, MMP-9： （39.96±1.75） ng/ml], P〈0.05. Conclusion： Probucol could decrease serum levels of gelatinases in patients with unstable angina pectoris, and possess effect of stabilization of atherosclerotic plaque.
出处
《心血管康复医学杂志》
CAS
2011年第6期549-551,共3页
Chinese Journal of Cardiovascular Rehabilitation Medicine
基金
佳木斯大学科技项目(S2010-77)
